DK0757557T3 - Fremgangsmåde til induktion af T-celle-tolerance over for et vævs- eller organtransplantat - Google Patents

Fremgangsmåde til induktion af T-celle-tolerance over for et vævs- eller organtransplantat

Info

Publication number
DK0757557T3
DK0757557T3 DK95917593T DK95917593T DK0757557T3 DK 0757557 T3 DK0757557 T3 DK 0757557T3 DK 95917593 T DK95917593 T DK 95917593T DK 95917593 T DK95917593 T DK 95917593T DK 0757557 T3 DK0757557 T3 DK 0757557T3
Authority
DK
Denmark
Prior art keywords
inducing
tissue
cell tolerance
organ graft
graft
Prior art date
Application number
DK95917593T
Other languages
Danish (da)
English (en)
Inventor
Randolph J Noelle
Fiona H Durie
David C Parker
Michael C Appel
Nancy E Philips
John P Mordes
Dale L Grenier
Aldo A Rossini
Original Assignee
Dartmouth College
Univ Massachusetts Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, Univ Massachusetts Medical filed Critical Dartmouth College
Application granted granted Critical
Publication of DK0757557T3 publication Critical patent/DK0757557T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
DK95917593T 1994-04-25 1995-04-25 Fremgangsmåde til induktion af T-celle-tolerance over for et vævs- eller organtransplantat DK0757557T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/234,987 US5683693A (en) 1994-04-25 1994-04-25 Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PCT/US1995/004832 WO1995028957A2 (fr) 1994-04-25 1995-04-25 Procedes servant a provoquer la tolerance des lymphocytes t a une greffe de tissu ou d'organe

Publications (1)

Publication Number Publication Date
DK0757557T3 true DK0757557T3 (da) 2005-05-23

Family

ID=22883593

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95917593T DK0757557T3 (da) 1994-04-25 1995-04-25 Fremgangsmåde til induktion af T-celle-tolerance over for et vævs- eller organtransplantat

Country Status (34)

Country Link
US (4) US5683693A (fr)
EP (2) EP0757557B1 (fr)
JP (1) JP2974415B2 (fr)
KR (1) KR100468330B1 (fr)
CN (1) CN1134266C (fr)
AP (1) AP764A (fr)
AT (1) ATE288281T1 (fr)
AU (1) AU710925B2 (fr)
BG (1) BG62121B1 (fr)
BR (1) BR9507509A (fr)
CA (1) CA2188672A1 (fr)
CZ (1) CZ291266B6 (fr)
DE (1) DE69533984T2 (fr)
DK (1) DK0757557T3 (fr)
EE (1) EE03516B1 (fr)
ES (1) ES2237757T3 (fr)
FI (1) FI118792B (fr)
GE (1) GEP20022648B (fr)
HU (1) HU221752B1 (fr)
IS (1) IS2118B (fr)
LT (1) LT4309B (fr)
LV (1) LV11785B (fr)
MD (1) MD1444B2 (fr)
NO (2) NO319787B1 (fr)
NZ (1) NZ284905A (fr)
OA (1) OA10591A (fr)
PL (1) PL180031B1 (fr)
PT (1) PT757557E (fr)
RO (1) RO114743B1 (fr)
RU (1) RU2169009C2 (fr)
SI (1) SI9520057A (fr)
SK (1) SK136996A3 (fr)
UA (1) UA44892C2 (fr)
WO (1) WO1995028957A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
NZ273207A (en) * 1993-09-02 1997-09-22 Dartmouth College Igg antibodies gp39 (cd40)
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997034633A1 (fr) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
EP1754490A3 (fr) * 1997-06-20 2010-01-20 Biogen Idec MA Inc. Thérapie de blocage par CD154 pour transplantation de tissus d'ilots pancréatiques chez les primates
HUP0003160A3 (en) * 1997-06-20 2002-09-30 Biogen Idec Ma Inc Cambridge The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
KR100711210B1 (ko) * 1998-07-30 2007-04-24 리젼츠 오브 더 유니버시티 오브 미네소타 ｇｐ３９ 길항제를 사용한 동종 또는 이종 Ｔ-세포의 생체외 처리
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) * 1999-11-25 2001-01-27 Камакин Владислав Владимирович Способ индивидуального подбора оптимального питания человека
WO2001079555A2 (fr) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles des membres de la famille jak/stat dans l'induction de la tolerance
CN1441675A (zh) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
EP1289554A4 (fr) * 2000-06-02 2004-05-26 Univ Minnesota Procede immunotherapeutique permettant de prevenir le rejet de cellules insulaires
EP1299542A2 (fr) * 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2001273174B2 (en) 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
CA2364983A1 (fr) * 2000-12-13 2002-06-13 John R. Coleman Molecules d'acide nucleique et polypeptides pour le catabolisme de l'acide abscisique
WO2002078743A1 (fr) * 2001-02-16 2002-10-10 University Of Rochester Compositions et techniques permettant de reduire les reactions aux transfusions
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
AU2002305716B2 (en) 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
CA2542984A1 (fr) * 2003-07-07 2005-01-27 David H. Wagner Methodes de prediction du developpement de maladies auto-immunes et traitement associe
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (fr) * 2005-12-07 2007-06-13 Schuler, Gerold, Prof. Dr. Procédés directs pour la culture de cellules dendritiques sans étape de centrifugation
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
FR2934140B1 (fr) * 2008-07-25 2010-09-03 Seb Sa Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
MX2012000086A (es) 2009-06-26 2012-06-12 Soricimed Biopharma Inc Peptidos derivados de soricidi y metodos para la la deteccion de canceres trpv-6 y suministro de farmaco.
WO2013013708A1 (fr) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Traitement du rejet aigu dans une transplantation rénale
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408859B1 (fr) * 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Anticorps monoclonaux contre cellules endothéliales activées
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
ATE239790T1 (de) * 1991-10-25 2003-05-15 Immunex Corp Antikörper gegen cd40-l
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
FI934751A (fi) * 1992-10-30 1994-05-01 Bristol Myers Squibb Co Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
NZ273207A (en) * 1993-09-02 1997-09-22 Dartmouth College Igg antibodies gp39 (cd40)
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
JP2974415B2 (ja) 1999-11-10
HU9602924D0 (en) 1996-12-30
EP0757557B1 (fr) 2005-02-02
AU2358595A (en) 1995-11-16
RU2169009C2 (ru) 2001-06-20
DE69533984T2 (de) 2006-04-27
ATE288281T1 (de) 2005-02-15
EP1530973A3 (fr) 2006-12-27
CZ291266B6 (cs) 2003-01-15
CZ312596A3 (en) 1997-03-12
RO114743B1 (ro) 1999-07-30
AU710925B2 (en) 1999-09-30
US6375950B1 (en) 2002-04-23
PL317022A1 (en) 1997-03-03
BR9507509A (pt) 1997-02-02
LT96165A (en) 1997-11-25
NO964440D0 (no) 1996-10-18
US7501124B2 (en) 2009-03-10
CA2188672A1 (fr) 1995-11-02
WO1995028957A3 (fr) 1995-11-23
HU221752B1 (hu) 2002-12-28
FI964272A0 (fi) 1996-10-23
AP9600906A0 (en) 1997-01-31
WO1995028957A2 (fr) 1995-11-02
EP1530973A2 (fr) 2005-05-18
HUT76091A (en) 1997-06-30
US5902585A (en) 1999-05-11
LT4309B (lt) 1998-03-25
LV11785B (en) 1998-02-20
MD1444B2 (ro) 2000-04-30
FI118792B (fi) 2008-03-31
NO20051182L (no) 1996-12-23
BG62121B1 (bg) 1999-03-31
IS4378A (is) 1996-10-22
EE9600162A (et) 1997-06-16
US20050152897A1 (en) 2005-07-14
LV11785A (lv) 1997-06-20
KR100468330B1 (ko) 2005-12-30
PT757557E (pt) 2005-05-31
CN1134266C (zh) 2004-01-14
MD970009A (en) 1999-01-31
SK136996A3 (en) 1999-01-11
JPH09512271A (ja) 1997-12-09
GEP20022648B (en) 2002-03-25
NO319787B1 (no) 2005-09-12
CN1150760A (zh) 1997-05-28
AP764A (en) 1999-09-16
OA10591A (en) 2002-07-15
EE03516B1 (et) 2001-10-15
ES2237757T3 (es) 2005-08-01
EP0757557A1 (fr) 1997-02-12
PL180031B1 (pl) 2000-12-29
BG100991A (en) 1998-01-30
US5683693A (en) 1997-11-04
UA44892C2 (uk) 2002-03-15
DE69533984D1 (de) 2005-03-10
IS2118B (is) 2006-06-15
FI964272A (fi) 1996-12-19
SI9520057A (sl) 1998-06-30
NO964440L (no) 1996-12-23
NZ284905A (en) 2004-10-29

Similar Documents

Publication Publication Date Title
DK0757557T3 (da) Fremgangsmåde til induktion af T-celle-tolerance over for et vævs- eller organtransplantat
DE69621595D1 (de) Knochentransplantat-verbindungen
DE69729137D1 (de) Stent zur Implantation
DE69606194D1 (de) Chirurgisches transplantat/stent-system
DE69531399D1 (de) Kunstherz
DE59509539D1 (de) Zwischenwirbel-implantat
FR2729291B1 (fr) Implant rachidien
DK1378257T3 (da) Colagen-baseret transplantatprotese
DE69522470T2 (de) Blutgefässprothese
DE69533993D1 (de) Endoluminales Transplantat
DK0747181T3 (da) Afgreningsordning
DE69629360D1 (de) Chirurgische prothese
DE29517393U1 (de) Herzbeutelprothese
PT9407T (pt) Colchao anatomico
NO952654D0 (no) Pulsåresimulering
DE69623074T2 (de) Methoden um Knochenschwund zu minimieren
DE69526389T2 (de) Offenes gewebe-implantat-system
FI955973A (fi) Keinotekoinen lasikuituvilla
ITMI950275A0 (it) Innesto
DE29513894U1 (de) Schienbeinplateau-Implantat
DE29504736U1 (de) Starrelastische Leiterplatte
DE69529211D1 (de) Künstliche Riffanlage
FI961467A (fi) Sähkökemiallinen menetelmä
FR2726464B3 (fr) Prothese vocale
KR960030026U (ko) 전복양식구